Search the Newsreel

XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS

XBiotech (NASDAQ:XBIT) reported a quarterly loss of $0.22 per share, significantly missing analysts' consensus estimate of a $0.03 profit by $0.25. Following the announcement, XBIT shares fell by $0.13 to $2.33, nearing its 52-week low, and the company's market capitalization is approximately $71 million. …

XBiotech: Q2 Earnings Snapshot

This article is an earnings snapshot for XBiotech's Q2 performance. It is a placeholder without actual financial details, suggesting that the full earnings report would contain the relevant financial data.

XBiotech (NASDAQ: XBIT) trims R&D spend yet remains loss-making in Q2 2026

XBiotech Inc. reported a Q2 2026 net loss of $6.7 million and a six-month net loss of $12.2 million, despite significantly reducing research and development and general and administrative expenses. The clinical-stage biopharmaceutical company does not anticipate generating revenue in 2026 and expects continued …

(RGNX) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-driven analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting mixed sentiment and a mid-channel oscillation pattern. It outlines institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. The analysis also includes a …

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) for alleged federal securities law violations. The lawsuit claims that REGENXBIO made materially false and misleading statements regarding the development and commercialization of RGX‑111 for severe MPS I. …

H.C. Wainwright lowers Regenxbio stock price target on equity offering

H.C. Wainwright has lowered its price target for Regenxbio (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's public offering of common stock in July 2026. This adjustment comes as Regenxbio reported Q2 2026 revenue of $108 million, including a …

XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for XBiotech Inc (XBIT), focusing on future EPS and revenue growth estimates. As of August 9, 2026, the company's stock is trading at 2.275 USD, with a market cap of 69.36M. The forecast section includes details on EPS, …

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of REGENXBIO Inc. to Contact the Firm Today!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO made materially false and misleading statements regarding the development …

Regenxbio Inc (RGNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

REGENXBIO (RGNX) Stock Drops Despite Profit Surprise And Longer Cash Runway

REGENXBIO (RGNX) experienced a nearly 5% stock drop despite reporting a surprise profit of US$0.43 EPS and US$108 million in revenue for Q2 2026, swinging from a significant loss. The company also extended its cash runway into Q4 2027 due to funding from AbbVie …

XBiotech Inc (XBIT) Stock News Today

This article from TradingKey provides a news and analysis page for XBiotech Inc (XBIT) stock. It shows the current stock price, market cap, and links to various financial data and analytical tools. The page indicates that more news is expected soon.

Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)

Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss

Xenetic Biosciences reported its Q2 2026 financial results, showing approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company ended the quarter with $6.5 million in cash and highlighted expanded translational research and collaborations for its DNase platform. Business …

Xenetic partner receives Israeli approvals for lymphoma study

Xenetic Biosciences reported its Q2 2026 financial results, highlighting approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company announced that its collaboration partner, PeriNess Ltd., received Israeli regulatory approvals to conduct an exploratory study of DNase I in …

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Xenetic Biosciences announced its second-quarter 2026 financial results, emphasizing continued progress with its proprietary DNase platform. The company reported a 12% increase in royalty revenue due to a sublicense agreement with Takeda Pharmaceuticals, while R&D expenses decreased and G&A expenses rose due to legal …

REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% Upside

Analysts have raised REGENXBIO Inc.'s average 12-month price target from $26 to $26.17, indicating a potential upside of approximately 149% from its August 5 closing price. The consensus rating for RGNX remains a "Buy" among 12 analysts, with 11 recommending a Buy and 1 …

Barclays downgrades Regenxbio stock rating on regulatory uncertainty

Barclays downgraded Regenxbio Inc. (NASDAQ:RGNX) to Equalweight from Overweight, setting a price target of $12.00 due to regulatory uncertainty surrounding its Duchenne muscular dystrophy (DMD) program and competitive landscape for wet age-related macular degeneration (wet AMD). Despite a recent 16% stock increase, the firm …

Xenetic Biosciences: Q2 Earnings Snapshot

Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary

Xenetic Biosciences, Inc. (XBIO) reported its 2026 quarterly results with revenue of $660.6K, a 12% increase year-over-year, and a diluted loss per share of ($0.41). The company's net loss was ($929.7K), an increase of 35% from the prior year quarter. Revenue growth was primarily …

REGENXBIO (Nasdaq: RGNX) turns Q2 profit on $100M AbbVie milestone

REGENXBIO (Nasdaq: RGNX) reported a significant turnaround in Q2 2026, posting a net income of $22.7 million ($0.43 per share) compared to a $70.9 million net loss in Q2 2025. This profit was largely driven by $108.0 million in total revenues, primarily from a …

Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket

REGENXBIO reported Q2 2026 adjusted EPS of $0.43, significantly beating the $0.25 forecast, though revenue of $108.02 million missed estimates. Shares rose premarket due to a strengthened balance sheet, with pro forma cash exceeding $310 million after a $100 million AbbVie milestone and a …

REGENXBIO Inc. Quarterly Earnings Report

Form 8K Regenxbio Inc For: 6 August By Investing.com

This article announces the filing of a Form 8K by Regenxbio Inc. on August 6th. The content of the Form 8K itself is not detailed, but the article contextualizes it within broader financial market news and data provided by Investing.com.

REGENXBIO reports Q2 2026: $108.0M revenue, $22.7M net income, cash pro forma >$310M

REGENXBIO announced strong financial results for Q2 2026, with revenues reaching $108.0 million and net income at $22.7 million. The company's cash position, including July 2026 milestone and offering proceeds, stands at over $313 million pro forma. Key upcoming catalysts include a BLA initiation …

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Inc. reported its second quarter 2026 financial results, highlighting strong clinical execution and a solid cash runway. Key achievements include the AFFINITY DUCHENNE® trial meeting its primary endpoint, the initiation of the NAAVIGATE study for diabetic retinopathy, and FDA reaffirming the path forward …

REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and certain officers, alleging federal securities law violations. The lawsuit claims that REGENXBIO made false and misleading statements about the development and commercialization of its gene therapy RGX‑111, …

RGNX Looks 33.1% Undervalued on GF Value™ Despite Possible Value Trap

Regenxbio Inc (RGNX) is set to report its Q2 earnings, with analysts forecasting a significant year-over-year revenue increase despite caution reflected in recent estimate revisions. While GuruFocus's GF Value™ suggests RGNX is 33.1% undervalued, its GF Score™ of 60 highlights weak financial strength and …

Regenxbio Inc expected to post earnings of 6 cents a share - Earnings Preview

Regenxbio Inc. (RGNX) is projected to report earnings of 6 cents per share. This financial forecast is provided as an earnings preview by Refinitiv. The full article is available to TradingView subscribers, offering unlimited access to news sources.

Earnings Preview: Regenxbio to Report Financial Results Pre-market on August 06

This article announces that Regenxbio Inc. (RGNX) is scheduled to release its financial results pre-market on August 6. Analysts are expecting a consensus loss per share of -$0.98. The report will likely detail the company's performance and provide insights into its gene therapy programs.

REGENXBIO's second-quarter financial update is set for Aug. 6

REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and provide operational highlights. Investors and analysts can register for the webcast, with a …

(RGNX) Risk Channels and Responsive Allocation

This article provides a detailed analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting weak sentiment across all time horizons which supports a short bias. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes …

XBiotech Inc (XBIT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for XBiotech Inc (XBIT), highlighting its current score of 2.62, which ranks 201 out of 384 in the Biotechnology & Medical Research industry. The company's beta of 0.81 indicates it tends to underperform in bull markets but experiences …